Skip to main content
SpringerLink
Log in

The Development of Therapeutic Angiosuppression: Problems and Progress

  • Chapter
Angiogenesis in Health and Disease

Part of the book series: NATO ASI Series ((NSSA,volume 227))

Abstract

Research in tumor angiogenesis has progressed rapidly in the past 25 years, marked by four investigative phases: 1) first, the study of the pathophysiology of tumor-host interactions to reveal the link between tumor blood flow and its internal mileu; 1 2) second, the paradigm of neo-plastic and neovascular interdependence, regulated by a chemical substance, a “tumor angiogenesis factor”,2 3) third, the explosion in the New Biology led to the purification, cloning, and widespread availability of several classes of angiogenic polypeptide growth factors, receptors, monoclonal antibodies, oncogenes, and suppressive oncogenes;3-8 4) fourth the successful clinical treatment of an angiogenic disease using a biological response modifier,9 and the call for clinical trials for cancer patients using inhibitors of angiogenesis, with the promise of less toxi-city than standard chemotherapy.10-11 With a growing list of inhibitors from which to choose, 8, 11-20 what generic problems and possibilities do these agents pose?

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. P. M. Gullino and F. H. Grantham, Studies on the exchange of fluids between host and tumor. II. the blood flow of hepatomas and other tumors in rats and mice. JNCI 27:1465–1491 (1961).

    PubMed  CAS  Google Scholar 

  2. J. Folkman, Anti-angiogenesis: New concept for the therapy of solid tumors. Ann. Surg. 175:409–416 (1972).

    Article  PubMed  CAS  Google Scholar 

  3. J. Folkman and M. Klagsbrun, Angiogenic factors. Science 235:442–447 (1987).

    Article  PubMed  CAS  Google Scholar 

  4. D. Gospodarowicz, N. Ferrara, L. Schweigerer and G. Neufeld, Structural characterization and biological functions of fibroblast growth factor. Endocrine Rev. 8:95–114 (1987).

    Article  CAS  Google Scholar 

  5. T. Magiag, Molecular and cellular mechanisms of angiogenesis, in “Important Advances in Oncology”, Jr. DeVita, S. Hellman, S. A. Rosenberg, eds. Philadelphia: JB Lippincott, 85–89 (1990).

    Google Scholar 

  6. N. Vaisman, D. Gospodarowicz, G. Neufeld, Characterization of the receptors for vascular endothelial growth factor. J. Biol. Chem. 265:19461–19466 (1990).

    PubMed  CAS  Google Scholar 

  7. K. Schulze-Osthoff, W. Risau, E. Vollmer and C. Sorg, In situ detection of basic fibroblast growth factor by highly specific antibodies. Am. J. Pathol. 137:85–92 (1990).

    PubMed  CAS  Google Scholar 

  8. N. Bouck, Tumor angiogenesis: The role of oncogenes and tumor suppressor genes. Cancer Cells 2:179–185 (1990).

    PubMed  CAS  Google Scholar 

  9. J. Folkman, Successful treatment of an angiogenic disease. New Engl. J. Med. 320:1211–1212 (1989).

    Article  PubMed  CAS  Google Scholar 

  10. P. Denekamp, Vasculature as a target for tumor therapy. Prog. Appl. Microcirc. 4:28–38 (1984).

    Google Scholar 

  11. D. Ingber, T. Fujita and S. Kishimoto, Synthetic analogues of fumagillin that inhibit angiogenesis and tumor growth. Nature 348:555–560 (1990).

    Article  PubMed  CAS  Google Scholar 

  12. J. Folkman and D. E. Ingber, Angiostatic steroids: Method of discoveryand mechanism of action. Ann. Surg. 206:374–383 (1987).

    Article  PubMed  CAS  Google Scholar 

  13. M. E. Maragoudakis, M. Sarmonika and M. Panoutsacopoulou, Inhibition of basement membrane biosynthesis prevents angiogenesis. J. Pharmacol. Exper. Therap. 244:729–733 (1988).

    CAS  Google Scholar 

  14. H. Brem, R. J. Tamargo, C. Guerin, S. S. Brem, and H. Brem, Brain tumor angiogenesis, in: “Advances in Neuro-Oncology”, Mount Kisko, NY, FUtura Publishing Company, P.L. Kornblith and Walter M.D. (eds), pp. 89–102,(1988).

    Google Scholar 

  15. P. Madarnas, O. Benrezzak, V. N. Nigam, Prophylactic antiangiogenic tumor treatment. Anticancer Res. 897–902 (1989).

    Google Scholar 

  16. T. E. Malone, G. S. Gray, and J. Petro, Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 247:77–79 (1990).

    Article  Google Scholar 

  17. Y. Shing, J. Folkman and J. Weisz, Affinity of fibroblast growth factors for b-cyclodextrin tetradecasulfate. Anal. Biochem. 185: 108–111 (1990).

    Article  CAS  Google Scholar 

  18. S. Brem, D. Zagzag, A. M. Tsanaclis, Inhibition of angiogenesis and tumor growth in the brain: Suppression of endothelial cell turnover by penicillamine and the depletion of copper, an angiogenic cofactor. Am. J. Pathol. 137:1121–1142 (1990).

    PubMed  CAS  Google Scholar 

  19. J. Murata, I. Saiki, and T. Makabe, Inhibition of tumor-induced angiogenesis by sulfated chitin derivatives. Cancer Res. 51:22–26 (1991).

    PubMed  CAS  Google Scholar 

  20. R. Tamargo, R. A. Bok and H. Brem, Angiogenesis inhibition by minocycline. Cancer Res. 51:672–675 (1976).

    Google Scholar 

  21. D. M. Noden, Embryonic origins and assembly of blood vessels. Am. Rev. Resp. Dis. 140:1097–1103 (1989).

    PubMed  CAS  Google Scholar 

  22. R. M. Shymko and L. Glass, Cellular and geometric control of tissue growth and mitotic instability. J. Theor. Biol. 63:355–374 (1976)

    Article  PubMed  CAS  Google Scholar 

  23. J. H. Burchenal, Adjuvant therapy - theory, practice and potential. Cancer 37:46–56 (1976).

    Article  PubMed  CAS  Google Scholar 

  24. C. A. Nichol, Pharmacokinetics: Selectivity of action related to physiochemical properties and kinetic patterns of anticancer drugs. Cancer 40:519–528 (1977).

    Article  PubMed  CAS  Google Scholar 

  25. M. J. Banda, D. R. Knighton, T. K. Hunt and Z. Werb, Isolation of nonmitogenic angiogenesis factors from wound fluid. Proc. Natl. Acad. Sci., USA 79:7773–7777 (1982).

    Article  PubMed  CAS  Google Scholar 

  26. J. L. Gross, D. Hertel, W. F. Herblin, M. Neville and S. S. Brem, Inhibition of basic fibroblast growth factor-induced angiogenesis and glioma tumor growth in vivo. Proc. Am. Assoc. Cancer Res. 32:57 (Abstr. #338) (1991).

    Google Scholar 

  27. K. S. Stenn, L. A. Fernandez and S. J. Tirrell, The angiogenic properties of the rat vibrissa hair follicle associate with the bulb. J. Invest. Dermatol. 90:409–411 (1988).

    Article  PubMed  CAS  Google Scholar 

  28. D. Gospodarowicz, and K. Thakral, Production of a corpus luteum angiogenic factor responsible for proliferation of capillaries and neovascularization of the corpus luteum. Proc. Natl. Acad. Sci. USA 75:847–851 (1978).

    Article  PubMed  CAS  Google Scholar 

  29. B. R. Zetter, Angiogenesis, State of the art. Chest 93 (3):1595–1665 (1988).

    Article  Google Scholar 

  30. N. T. Chen, E. J. Corey and J. Folkman, Potentiation of angiostatic steroids by a synthetic inhibitor of arylsulfatase. Lab. Invest. 59:453–455 (1988).

    PubMed  CAS  Google Scholar 

  31. J. W. Wilks, T. F. Dekoning, J. M. Cocuzza, Suramin plus angiostatic steroids suppress tumor growth (Abstr.) Proc. Am. Assoc. Cancer Res. 31:60 (1990).

    Google Scholar 

  32. R. Auerbach, L. Alby and L. W. Morrisey, Expression of organ-specific antigens on capillary endothelial cells. Microvasc. Res. 29:401–411 (1985).

    Article  PubMed  CAS  Google Scholar 

  33. S. Brem, R. S. Cotran, and J. Folkman, Tumor angiogenesis: a quantitative method for histologic grading. J. Natl. Cancer Inst. 48: 347–356 (1972).

    PubMed  CAS  Google Scholar 

  34. D. Zagzag, S. Brem, and F. Robert, Neovascularization and tumor growth in the brain. A model for experimental studies of angiogenesis and the blood-brain barrier. Am. J. Pathol. 131:361–372 (1988).

    PubMed  CAS  Google Scholar 

  35. S. Brem, H. Brem and J. Folkman, Prolonged tumor dormancy by prevention of neovascularization in the vitreous. Cancer Res. 36:2807–2812 (1976).

    PubMed  CAS  Google Scholar 

  36. G. H. Hepner and B. E. Miller, Tumor heterogeneity: biological implications and therapeutic consequences. Cancer Metast. Rev. 2:5–23 (1983).

    Article  Google Scholar 

  37. A. M. Tsanaclis, S. S. Brem, S. Gately, H. M. Schipper and E. Wang, Statin immunolocalization in human brain tumors: Detection of noncycling cells using a novel marker of cell quiescence. Cancer in press (1991).

    Google Scholar 

  38. T. Nagashima, T. Hoshino and K. G. Cho, Proliferative potential of vascular components in human glioblastoma multiforme. Acta Neuropathol. (Berl) 73:301–305 (1987).

    Article  CAS  Google Scholar 

  39. B. Hobson and J. Denekamp, Endothelial proliferation in tumours and normal tissues. Continous labelling studies. Br. J. Cancer 49: 405–413 (1984).

    Article  PubMed  CAS  Google Scholar 

  40. J. L. Olson, D. W. Beck, D. S. Warner and H. Coester, The role of new vessels and macrophages in the development and resolution of ederma following a cortical freeze lesion in the mouse. J. Neuropath. Exper. Neurol. 46:682–694 (1987).

    Article  CAS  Google Scholar 

  41. B. R. Deane, J. Greenwood, P. L. Lantos, and O. E. Pratt, The vasculature of experimental brain tumours: Part 4. The quantification of vascular permeability. J. Neurol. Sci. 65:59–68 (1984).

    Article  PubMed  CAS  Google Scholar 

  42. T. Jain. Determinants of tumour blood flow: A review. Cancer Res. 48:2641–2658 (1988).

    PubMed  CAS  Google Scholar 

  43. S. E. Brien, D. Zagzag, S. Brem, Rapid in situ cellular kinetics of intracerebral tumor angiogenesis using a monoclonal antibody to bromodeoxyuridine. Neurosurgery 25:715–719 (1989).

    Article  PubMed  CAS  Google Scholar 

  44. H. Brem and J. Folkman, Inhibition of tumor angiogenesis mediated by cartilage. J. Exper. Med. 141:427–438 (1975).

    Article  CAS  Google Scholar 

  45. S. Brem, I. Preis, R. Langer, Inhibition of neovascularization by an extract derived from vitreous. Am. J. Ophthalmol. 84:323–328 (1977).

    PubMed  Google Scholar 

  46. J. Folkman, R. Langer, R. J. Linhardt, Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science 221:719–725 (1983).

    Article  PubMed  CAS  Google Scholar 

  47. S. Taylor and J. Folkman, Protamine is an inhibitor of angiogenesis. Nature 297:307–312 (1982).

    Article  PubMed  CAS  Google Scholar 

  48. H. Brem, M. S. Mahaley Jr., N. A. Vick, Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J. Neurosurg. 74:441–446 (1991).

    Article  PubMed  CAS  Google Scholar 

  49. H-L. Peterson, Tumor angiogenesis inhibition by prostaglandin synthetase inhibitors. Anticancer Res. 6:251–254 (1986).

    PubMed  CAS  Google Scholar 

  50. J. Folkman and M. Klagsbrun, A family of angiogenic peptides. Nature 329:671–672 (1987).

    Article  PubMed  CAS  Google Scholar 

  51. J. R. Merwin, W. Newman and L. D. Beall, Vascular cells respond differentially to transforming growth factors Beta.1 and Beta2 in vitro. Am. J. Pathol. 138:37–51.(1991).

    PubMed  CAS  Google Scholar 

  52. M. Sjölund, and J. Thyberg, Suramin inhibits binding and degradation of platelet-derived growth factor in arterial smooth muscle cells but does not interfere with autocrine stimulation of DNA synthesis Cell Tissue Res. 256:35–43 (1989).

    Article  PubMed  Google Scholar 

  53. K. Ono, H. Nakane and M. Fukushima, Differential inhibition of various deoxyribonucleic and ribonucleic acids by suramin. Eur. J. Biochem. 172:349–353 (1988).

    Article  PubMed  CAS  Google Scholar 

  54. C. A. Stein, R. V. LaRocca and R. Thomas, Suramin: An anticancer drug with a unique mechanism of action. J. Clin. Oncol. 7:499–508 (1989).

    PubMed  CAS  Google Scholar 

  55. J. Fantini, T.-J. Guo, J. Marvaldi and G. Rougon, Suramin inhibits proliferation of rat glioma cells and alters N-CAM cell surface expression. Int. J. Cancer 45:554–561 (1990).

    Article  PubMed  CAS  Google Scholar 

  56. J. Plouët and H. Moukadari, Characterization of the receptor to vasculotropin on bovine adrenal cortex-derived capillary endothelial cells. J. Biol. Chem. 265:22071–22074 (1990).

    PubMed  Google Scholar 

  57. A. Yayon, and M. Klagsbrun, Autocrine transformation by chimeric signal peptide-basic fibroblast growth factor: Reversal by suramin Proc. Natl. Acad. Sci. USA 87:5346–5350 (1990).

    Article  PubMed  CAS  Google Scholar 

  58. C. Betzholtz, A. Johnsson, C.-H. Heldin, and B. Westermark, Efficient reversion of simian sarcoma virus-transformation and inhibition of growth factor-induced mitogenesis by suramin. Proc. Natl. Acad. Sci, USA 83:6440–6444 (1986).

    Article  Google Scholar 

  59. M. Ciomei, E. Pesenti and F. Sola, Antagonistic effect of suramin on bFGF: In vitro and in vivo results (Abstr.). 16th LH Gray Conference: Vasculature as a target for anticancer therapy, Manchester England, Sept. 17–21 (1990).

    Google Scholar 

  60. R. V. LaRocca, M. R. Cooper, M. Uhrich, Use of suramin in treatment of prostatic carcinoma refractory to conventional hormonal manipulation. Urol. Clin. NA 18:123–129 (1991).

    CAS  Google Scholar 

  61. R. V. LaRocca, C. A. Stein, R. Danesi, A pilot study of suramin in the treatment of metastatic renal carcinoma. Cancer 67:1509–1513 (1991).

    Article  CAS  Google Scholar 

  62. Committee on Science, Engineering and Public Policy. In: “New Pathways in Science and Technology,” National Academy-Random House Press, New York (1985).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neurosurgual Oncology, North Western Medical Faculty Found. Inc, Streetville Center, 233 East Evie, Suite 500, Chicago, Ill., 60611, USA

    Steven Brem

Authors
  1. Steven Brem
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Patras Medical School, Patras, Greece

    Michael E. Maragoudakis

  2. University of Turin Medical School, Turin, Italy

    Pietro Gullino

  3. University of Wisconsin Medical School, Milwaukee, Wisconsin, USA

    Peter I. Lelkes

Rights and permissions

Reprints and permissions

Copyright information

© 1992 Springer Science+Business Media New York

About this chapter

Cite this chapter

Brem, S. (1992). The Development of Therapeutic Angiosuppression: Problems and Progress. In: Maragoudakis, M.E., Gullino, P., Lelkes, P.I. (eds) Angiogenesis in Health and Disease. NATO ASI Series, vol 227. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3358-0_27

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-3358-0_27

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-6481-8

  • Online ISBN: 978-1-4615-3358-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation